openPR Logo
Press release

Biosimilars Market Outlook to 2025 | Swot Analysis and Market strategies By Key Players - Biocon, Samsung BioLogics, Mylan N.V., Amgen Inc., Celltrion, Reddy’s Laboratories Ltd. and others.

11-22-2018 05:28 AM CET | Health & Medicine

Press release from: The Insight Partners

/ PR Agency: Biosimilars Industry
Biosimilars Market

Biosimilars Market

The growth of the global biosimilars market can be attributed to the growing demand of pharmaceutical drug supplements, especially for the high priced patented drugs expected to upsurge the growth of the market. Additionally, increasing incidences of chronic diseases add novel opportunities for the global biosimilars market over the forecast period.

This report includes the profiles of key biosimilars manufacturing companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, products and services offered, financial information of last 3 years, key development in past five years.

Get Sample PDF Copy @ http://bit.ly/2Tt7zQG

A biosimilar is a biological product which is similar to an FDA approved biologic product of another manufacturer. Owing to the complexities associated with development & manufacture of biosimilar products, these are manufactured by companies with highly skillful workforce and deep scientific expertise. The FDA approval process for biosimilar products is rigorous and enables high safety to the end users.

Key players influencing the market are

Some of the key players influencing the market are Teva Pharmaceutical Industries Ltd., Pfizer Inc., Biocon, Samsung BioLogics, Mylan N.V., Amgen Inc., Celltrion, Healthcare Co.,Ltd., Sandoz International GmbH, STADA Arzneimittel AG, Dr. Reddy’s Laboratories Ltd. and others.

A biosimilar is a biological product which is similar to FDA approved biologic product of the manufacturer. A biosimilar product is a substance which is derived from living cells and used for the treatment of various diseases. In terms of safety and effectiveness, a biosimilar product has no clinically meaningful differences from the reference product. The only minor difference in clinically inactive components is allowable in biosimilar product. It is also known as reference products that are used for the development and manufacturing of biological products such as medicines.

On the basis of product the market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, peptides and others. The recombinant non-glycosylated proteins market is further segmented into insulin, recombinant human growth hormone, granulocyte colony-stimulating factor and interferons. The recombinant glycosylated proteins segment is bifurcated into monoclonal antibodies and erythropoietin. The peptides segment is also classified into calcitonin and glucagon. Based on application the market is segmented into oncology, autoimmune diseases, chronic diseases, blood disorders, infectious diseases, growth hormone deficiency and others.

North America is expected to dominate the biosimilars market in the global arena due to the increasing incidences of cancer, diabetes and autoimmune diseases in the region. Moreover, the Asia-Pacific region is anticipated to show a significant growth rate over the next five years in the global biosimilars market due to the increasing geriatric population in the region.
The report analyzes factors affecting market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend.

Buy Complete Report @ http://bit.ly/2TwroXg

The report provides a detailed overview on the industry including both qualitative and quantitative information. It provides overview and forecast of the global biosimilars based on product and application. It also provides market size and forecast till 2025 for overall biosimilars market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East &Africa (MEA) and South & Central America. The market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 13 countries globally along with current trend and opportunities prevailing in the region.

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilars Market Outlook to 2025 | Swot Analysis and Market strategies By Key Players - Biocon, Samsung BioLogics, Mylan N.V., Amgen Inc., Celltrion, Reddy’s Laboratories Ltd. and others. here

News-ID: 1390469 • Views: 249

More Releases from The Insight Partners

Anomaly Detection Market Size to Garner Exponential Accruals by 2027 with Anodot …
The Industry Report “Anomaly Detection Market” provides a clear picture of the Current Market Scenario which includes past and estimated future size with respect to Value and Volume, Technological Advancement, Macro Economical and Governing Factors in the Anomaly Detection market. Anomaly detection is the identification of the points, events items that are not expected to happen in the process. Anomaly detection is used for various domains such as fault detection, intrusion
Global Enterprise IP Management Software Market Outlook to 2025 - Anaqua, Cardin …
The Industry Report “Enterprise IP Management Software Market” provides a clear picture of the Current Market Scenario which includes past and estimated future size with respect to Value and Volume, Technological Advancement, Macro Economical and Governing Factors in the Enterprise IP Management Software market. IP Assets are valuable and flexible key assets for creating and sustaining enterprise competition. Globalization and trade liberalization have made most it significant for all enterprises including
Financial Services Application Market 2027 Analysis By Growing Companies: Fiserv …
Financial services application is a software program that facilitates the management of money related processes. Globalization and digitization of financial institutions and infrastructure have cultivated the need for risk-free financial services. Rise of big data analytics and business intelligence solutions are revolutionizing the fintech industry. Financial institutions are increasingly incorporating AI to improve customer experiences. The report presents the current market analysis scenario, future and future opportunities, revenue growth, prices and
Event Stream Processing Market to 2027 - Leading Key Players Google, IBM, Inform …
The analysis of the global Event Stream Processing Market 2027 is an in-depth study of the Event Stream Processing industry, which focuses on global market trends. The report aims to provide an overview of the global market for Event Stream Processing with detailed market segmentation by product / application and by region. The global market for Event Stream Processing is expected to experience strong Growth over the forecast period. The reports

All 5 Releases


More Releases for Biosimilars

PHASE-XS – Access To Life Changing Biosimilars
Biopharmaceutical is one of the fastest growing industries with addition of numerous biologics that provide novel treatment modalities for life-threatening and rare diseases. Biologics are produced from living organisms through unique manufacturing and purification processes. It includes a wide variety of products such as vaccines, blood, blood components, cells, allergens, genes, tissues, and recombinant proteins that are derived from human, animal or microorganisms by using biotechnological procedures. Some examples for
Global Biosimilars Market Research Report
This report studies the global Biosimilars market status and forecast, categorizes the global Biosimilars market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Pfizer Sandoz International GmbH Teva Pharmaceuticals Industries Amgen Inc Biocon Dr. Reddy’s Laboratories F. Hoffmann-La Roche Celltrion Samsung Bioepis
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Biosimilar is a medicine developed on the original biological reference product. The production process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar product is unique from the other. Biosimilar manufactures use different culture conditions, master cell lines, purification techniques, and raw materials. This in turn, helps meet the rising prevalence of diabetes due to inadequate healthcare services, rising prevalence of obesity, For instance, According to 2013 American
Humira Biosimilars Clinical Trial Insight
“Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. The patent protection assigned to Humira will expire in 2016 for US and 2018 for European market.
Enbrel Biosimilars Clinical Trial Insight
“Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilars version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 5 biosimilar version of Enbrel are commercially available in Iran, Mexico, India, UK and Australia. The patent on Enbrel was originally set to expire on